Absci, a generative AI drug creation company headquartered in Vancouver, Washington, announced its partnership with Memorial Sloan Kettering Cancer Center to co-develop up to six antibody therapies in oncology.
Founder and CEO Sean McClain remarked, “By combining MSK’s research expertise with our generative AI drug creation platform, we have the potential to unlock critical advances toward treating this devastating disease.” Emerging from the Pacific Northwest, Absci represents the region’s growing influence on the national biotech sector.